GLP-1 receptor agonists

GLP-1 receptor agonists, semaglutide (sold as Ozempic and Wegovy) and the dual GLP-1/GIP agonist tirzepatide (Mounjaro, Zepbound), are incretin-mimetic drugs that suppress appetite and slow gastric emptying. Born as type-2 diabetes treatments, they have become the most effective obesity pharmacotherapy ever tested in randomized trials. The 2023 SELECT trial added something rarer: proof that a weight-loss drug cuts hard cardiovascular outcomes.

What the trials show

In the STEP 1 trial, semaglutide produced roughly 15% body-weight loss versus about 3% with placebo [1]. Tirzepatide went further: SURMOUNT-1 found approximately 21% weight loss [2]. No prior obesity drug came close, and those numbers approach what bariatric surgery achieves. These are not surrogate endpoints or biomarker shifts, they are kilograms lost by real patients over the course of a controlled trial.

The SELECT trial enrolled non-diabetic adults with obesity and established cardiovascular disease and found that semaglutide reduced major cardiovascular events by approximately 20% [3]. That result matters because cardiovascular death and heart attack are what ultimately kills most people with obesity. A drug that moves those numbers, not the scale, belongs in a different category from its predecessors.

The lean-mass problem

About 40% of the weight lost on GLP-1 agonists is lean mass, not fat [4]. That figure sounds alarming, but researchers note that a similar proportion is lost during calorie-restricted diets generally, and functional measures are largely preserved in the trials. The muscle loss is real, though, and it matters especially for older adults building or protecting the muscle they'll need for the next decade. Resistance training and adequate protein intake appear to blunt the lean-mass decline, a point emphasized by Peter Attia and the ZOE research group [5, 6].

These drugs don't work once and stop

Stopping a GLP-1 agonist reverses most of the benefit. In one year after discontinuation, roughly two-thirds of the weight comes back [7]. That framing, chronic disease requires chronic treatment, is uncomfortable for many patients but is exactly what the data show. Planning to use semaglutide or tirzepatide for six months and then coast is a plan for regain.

Side effects and open questions

Gastrointestinal symptoms, nausea, vomiting, constipation, are the most common adverse effects, typically appearing early and fading with time; gallbladder disease and pancreatitis are rare but documented [8]. Several other signals are still emerging: possible benefit in metabolic liver disease (MASH), kidney-protective effects under study in the FLOW trial, and early data suggesting reductions in alcohol use and addictive behaviors. Verhoeven's analysis suggests liver and addiction benefits may prove meaningful, though these remain active areas of investigation rather than settled conclusions [5]. Claims that GLP-1 agonists will meaningfully extend lifespan are speculative; the weight and cardiovascular data are plausible mechanistic bridges, but no lifespan evidence exists yet [5].

Putting it together

GLP-1 agonists represent a genuine advance in treating obesity and reducing cardiovascular risk. The weight loss is large, the cardiovascular outcome data are hard, and the side-effect profile is manageable for most people. The cost is real: lean-mass loss, near-certain regain on stopping, and the practical and financial demands of indefinite use. Pairing these drugs with resistance training and sufficient protein is not optional self-optimization, it's what the muscle-loss data argue for [5, 6].

Where the evidence is contested

The lean-mass figures sit at the center of an active disagreement. Some researchers read the functional-preservation data as reassurance that the 40% lean-mass fraction [4] is clinically acceptable, comparable to ordinary dieting. Others, including voices cited on this page [5, 6], make two objections. First, acceptable in a trial population does not mean acceptable for an individual trying to preserve muscle into their sixties and seventies. Second, the trial protocols did not include structured resistance training. Neither side disputes the number. They dispute how worried you should be about it.

The cardiovascular benefit from SELECT [3] is not meaningfully contested, but its mechanism is. Does the 20% event reduction come from weight loss, anti-inflammatory effects, direct cardiac action, or some combination? This remains an open research question. The answer matters for deciding who benefits most, and the field has not settled it.

References

1. Wilding et al. 2021 (STEP 1), NEJM — semaglutide weight loss · PubMed 33567185
2. Jastreboff et al. 2022 (SURMOUNT-1), NEJM — tirzepatide · PubMed 35658024
3. Lincoff et al. 2023 (SELECT), NEJM — semaglutide & CV events · PubMed 37952131
4. GLP-1 body composition — ~40% lean-mass loss (STEP/SURMOUNT DXA) · PubMed 39996356
5. Attia #314 — obesity treatment, GLP-1 agonists, protein
6. ZOE — Amati: 40% of weight lost isn't fat (Ozempic rules)
7. Wilding et al. 2022 (STEP 1 extension), DOM — weight regain · PubMed 35441470
8. ZOE — Robert Kushner: does Ozempic really work?